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Abstract
Melphalan flufenamide (hereinafter referred to as “melflufen”) is a peptide-conju-
gated drug currently in phase 3 trials for the treatment of relapsed or refractory multi-
ple myeloma. Due to its lipophilic nature, it readily enters cells, where it is converted 
to the known alkylator melphalan leading to enrichment of hydrophilic alkylator 
payloads. Here, we have analysed in vitro and in vivo the efficacy of melflufen on 
normal and cancerous breast epithelial lines. D492 is a normal-derived nontumori-
genic epithelial progenitor cell line whereas D492HER2 is a tumorigenic version of 
D492, overexpressing the HER2 oncogene. In addition we used triple negative breast 
cancer cell line MDA-MB231. The tumorigenic D492HER2 and MDA-MB231 cells 
were more sensitive than normal-derived D492 cells when treated with melflufen. 
Compared to the commonly used anti-cancer drug doxorubicin, melflufen was sig-
nificantly more effective in reducing cell viability in vitro while it showed compara-
ble effects in vivo. However, melflufen was more efficient in inhibiting metastasis of 
MDA-MB231 cells. Melflufen induced DNA damage was confirmed by the expres-
sion of the DNA damage proteins ƴH2Ax and 53BP1. The effect of melflufen on 
D492HER2 was attenuated if cells were pretreated with the aminopeptidase inhibi-
tor bestatin, which is consistent with previous reports demonstrating the importance 
of aminopeptidase CD13 in facilitating melflufen cleavage. Moreover, analysis of 
CD13high and CD13low subpopulations of D492HER2 cells and knockdown of CD13 
showed that melflufen efficacy is mediated at least in part by CD13. Knockdown 
of LAP3 and DPP7 aminopeptidases led to similar efficacy reduction, suggesting 
that also other aminopeptidases may facilitate melflufen conversion. In summary, we 
have shown that melflufen is a highly efficient anti-neoplastic agent in breast cancer 
cell lines and its efficacy is facilitated by aminopeptidases.
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1 |  INTRODUCTION
Breast cancer is a heterogeneous group of diseases divided 
into several subclasses with distinct prognosis and survival 
outcomes. Even though the 5-year survival rate of breast can-
cer is over 90%, due to the high prevalence, it is a leading 
cause of cancer-related death in women.1,2 Based on gene 
expression analysis, breast cancer can be classified into five 
subclasses, Normal-like, Luminal A and B, HER2 amplified, 
and triple negative (TN) with TN and HER2 amplified breast 
cancer patients having the worst prognosis.1,3,4
Cellular origin of breast cancer is debated, but many stud-
ies link it to resident stem or progenitor cells in the breast 
gland.5,6 Modeling breast morphogenesis and cancer progres-
sion in vitro using cells with stem cell properties is import-
ant to both unravel the cellular and molecular mechanism of 
breast cancer and to improve screening for efficient cancer 
drugs.2,7
D492 is a breast epithelial cell line generated from reduc-
tion mammoplasty.2,8 Its stem cell-like properties are evident 
in its ability to propagate to both luminal and myoepithelial 
cells in culture. In the 3D microenvironment, D492 generates 
branching structures similar to terminal duct lobular units 
(TDLUs) in vivo.8 D492HER2 is a cancerous derivative of 
the D492 line generated by overexpression of the HER2 on-
cogene.9 In contrast with the D492 line, which is nontumor-
igenic, D492HER2 forms aggressive tumors in mice.9 These 
isogenic cell lines have been used to study the molecular 
mechanism of branching morphogenesis and cancer progres-
sion in the breast gland.2,9-12
Melphalan is a well-known cancer drug used for decades 
for the treatment of various cancer types, and it is still widely 
used for hematological cancers today.13 It is an alkylating 
agent that works by adding an alkyl group to the guanine base 
of the DNA, resulting in an aberrant linkage between DNA 
strands, DNA breakage, and inhibition of DNA synthesis.14 
Melphalan is a hydrophilic drug, and as such, it does not pen-
etrate cell membranes easily, which is limiting to its antican-
cer potential. In contrast, melflufen (melphalan flufenamide), 
a new peptide-conjugated alkylator, is highly lipophilic and 
therefore penetrates the cell membrane easily.15 Inside the 
cell, melflufen is rapidly hydrolyzed into less lipophilic me-
tabolites that retain high alkylating potential, leading to their 
entrapment and accumulation.15
Aminopeptidases belong to a large family of enzymes 
that catalyze the cleavage of amino acids from the amino 
terminus of proteins or peptides and are shown to facilitate 
intracellular hydrolysis of melflufen.16 Aminopeptidases are 
involved in multiple cellular processes, and their expression 
and activity are frequently deregulated in cancer cells.16 For 
this reason, aminopeptidase inhibitors bestatin and tosedostat 
have been investigated in the clinical settings.16 Exploiting 
aminopeptidase activity to convert a lipophilic drug such as 
melflufen to an intracellular hydrophilic metabolite with high 
alkylating potential may offer an effective alternative thera-
peutic approach. Previously it has been shown that amino-
peptidase N (ANPEP or CD13) can hydrolyze melflufen, but 
it is largely unknown whether melflufen can be a substrate for 
other aminopeptidases.
Application of melflufen has mainly been focused on 
multiple myeloma, where it has shown promising results in 
phase 3 clinical trial in relapse and refractory patient pop-
ulation.13 Yet it is unexplored whether melflufen can be ef-
fective in other cancer types such as breast cancer. Here, we 
demonstrate the efficacy of melflufen in D492HER2 breast 
epithelial cells overexpressing the HER2 oncogene and the 
triple-negative cell line MDA-MB-231.
2 |  MATERIAL AND METHODS
2.1 | Cell culture
D492 and D492HER2 cells were cultured in H14 media 
supplemented with penicillin (100 U/mL) and strepto-
mycin (100  µg/mL) in culture flasks coated with colla-
gen I (Advanced Biomatrix), as described previously.1 
MDA-MB-231 cells (ATCC® HTB-26™) were maintained in 
Gibco™ DMEM media containing 10% fetal bovine serum 
(FBS) (Invitrogen) supplemented with penicillin (100 U/mL) 
and streptomycin (100  µg/mL). All cells were maintained 
at 37°C and 5% CO2 and subcultured at a ratio of 1:10, 1-2 
times/week. For 3D culture, 8000 cells were seeded on top-of 
Matrigel (Corning) and cultured for 5-days in H14 or DMEM 
medium, changing media every 2 days. After colonies were 
formed, drugs were added to the media and the effects on 
3D colonies were visualized with anEVOS FL Auto 2 Cell 
Imaging System (Thermo Fisher Scientific).
2.2 | Drugs
Melflufen and melphalan were obtained from Recipharm, 
Sweden, dissolved in DMSO and stored at −80°C. 
Doxorubicin was obtained from Actavis, Iceland. Bestatin 
was purchased from Sigma Aldrich and resuspended ac-
cording to the manufacturer´s protocol. All substances were 
further diluted in cell culture media to appropriate concentra-
tions prior to the start of experiments.
2.3 | Proliferation and cell viability assays
For proliferation assays 10 000 cells were seeded in 96 well 
plates, cultured for 24 h prior to the addition of drugs and in-
hibitors. Cells were incubated with various drug concentrations 
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in medium for 30  min thereafter medium was refreshed. 
Proliferation was monitored using an IncuCyte ZOOM 
(Sartorius). Graphical analysis of cell numbers was performed 
for selected time points, 48 and 72 h post drug application. Cell 
viability was assessed in a similar way but using a colorimetric 
assay with PrestoBlueTM cell viability reagent (Invitrogen).
2.4 | Protein isolation and Western blotting
Total protein content was extracted from cells using RIPA 
buffer (50 mmol L-1 tris-HCl (pH 7.4), 150 mmol L-1 NaCl, 
0.5% Igepal, 5 mmol L-1 EDTA (pH 8.0), 0.1% SDS supple-
mented with Halt Protease, and Phosphatase Inhibitor cocktail 
(Thermo Fisher). Equal volume of each sample was resolved 
on Tris-glycine SDS-polyacrylamide gels and transferred to a 
nitrocellulose membrane (Santa Cruz Biotechnology), blocked 
in blocking buffer (5% skim milk powder in PBS), and probed 
with primary antibodys overnight at 4°C (Actin B, Li-Cor 
Cat. No. 926-42212; γH2AX, Cell Signaling Technology, 
Cat. No. 80 312; H2AX, R&D Systems, Cat. No. MAB3406; 
DPP7, Proteintech, Cat. No. 19018-1-AP; LAP3, Santa 
Cruz Biotechnology, Cat. No. sc-398601; CD13, Santa Cruz 
Biotechnology, Cat. No. sc-51522; cleaved PARP (Asp214), 
Cell Signaling Technology, Cat. No. 5625; cleaved Caspase-3 
(Asp175), Cell Signaling Technology, Cat. No. 9664). Proteins 
were detected using horseradish peroxidase-conjugated sec-
ondary antibodies (Santa Cruz Biotechnology) and Pierce ECL 
detection substrate (Thermo Fisher). All western blot assays 
were replicated in triplicate, resolved bands normalized against 
actin and quantified using FIJI.
2.5 | Gene expression
Total RNA was extracted with TRI-Reagent (Life 
Technologies) and reverse transcribed using the SuperScript® 
IV First-Strand Synthesis System (Invitrogen). Quantitative 
real-time PCR was carried out using Luna® Universal qPCR 
Master Mix (New England Biolabs) with predesigned primer 
pairs CD13 (Hs.PT.56a.534906), LAP3 (Hs.PT.58.2647348), 
DPP7 (Hs.PT.58.39153978), using ß-2-microglobulin (Hs.
PT.58v.18759587) or GAPDH (Hs.PT.39a.22214836) as 
reference. Comparative CT values were determined in tripli-
cate using an ABI 7500 Real Time PCR instrument (Applied 
Biosystems).
2.6 | Transient knockdown of 
aminopeptidases by siRNA
Pre-designed Silencer® Select siRNAs against CD13 (s683), 
LAP3 (s27311) and Silencer® Select Negative Control No. 1 
(ThermoFischer Scientific), as well as siRNA against DPP7 
(Santa Cruz Biotechnology) were used at a concentration 
of 10  nmol L-1. For delivery of siRNA, Lipofectamine® 
RNAiMAX tranfection reagent (ThermoFischer Scientific) 
was used according to the manufacturer´s protocol. 48 h post-
transfection cells were incubated with the indicated drug con-
centrations for 30 min, and then cell viability was monitored 
using an IncuCyte ZOOM (Sartorius) or using a colorimetric 
assay with PrestoBlueTM cell viability reagent (Invitrogen) 
48 h post-incubation. Successful knockdown of target genes 
at the time point of drug application was confirmed by qRT-
PCR and Western blot.
2.7 | Immunostaining and Confocal imaging
Immunofluorescence was captured and visualized using an 
Olympus FV1200 confocal microscope (Olympus, Tokyo, 
Japan). Cells were fixed in formalin for 20 mins before stain-
ing. Antibodies used were BV421 γH2AX (pS139) (BD 
Horizon, Cat. No. 564  720), 53BD1 (R&D Systems, Cat. 
No. MAB18772), yH2Ax (pS139) (R&D Systems, Cat. No. 
AF2288), Alexa-Fluor phalloidin (Life Technologies, Cat. 
No. A12379), was used to stain for actin. DAPI was used for 
nuclear staining.
2.8 | Chick embryo chorioallantoic 
grafting assay
Fertilized White Leghorn eggs were incubated at 37.5°C with 
50% relative humidity for 9 days (Inovotion INC, France). On 
day E9, the chorioallantoic membrane (CAM) was dropped 
down by drilling a small hole through the eggshell into the 
air sac, and a 1 cm2 window was cut in the eggshell above 
the CAM. MDA -MB-231 or D492HER2 cells were detached 
with trypsin, washed with complete medium and suspended 
in graft medium. An inoculum of 1 × 106 cells was added 
onto the CAM of each egg. Eggs were then randomized into 
eight groups. On day E10, tumors became detectable, and 
were treated with either vehicle (1% DMSO in 1x PBS), dox-
orubicin at 50 µmol L-1 or melflufen at 12 µmol L-1, 50 µmol 
L-1, and 200 µmol L-1 per egg. For all conditions, the injec-
tion volume of 100 μl/egg, was dropped onto the tumor. On 
day E18 the upper portion of the CAM containing tumor was 
removed, washed in PBS and then directly transferred in PFA 
(fixation for 48 h). The tumor was then washed, carefully 
cut away from normal CAM tissue and weighed. Analysis 
of metastasis was done in parallel. Briefly, a 1 cm2 portion 
of the lower CAM was collected to evaluate the number of 
metastatic cells. Genomic DNA was extracted from the CAM 
and analyzed by qPCR with specific primers for human Alu 
sequences. Calculation of Cq for each sample, mean Cq and 
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relative amount of metastasis for each group was performed 
with the Bio-Rad® CFX Maestro® software. To estimate 
toxicity, eggs were checked at least every two days, for vi-
ability and visible macroscopic abnormalities. The number of 
dead embryos counted on day E18, combined with reported 
abnormalities was used to evaluate total toxicity.
2.9 | Statistical analysis
Two-way analysis of variance (ANOVA) using Tukey's mul-
tiple comparison test was performed using GraphPad Prism 
to test significance. P-values below 0.05 were considered sig-
nificant (*P ≤ .05, **P ≤ .01, ***P ≤ .001, ****P ≤ .0001).
3 |  RESULTS
3.1 | Breast cancer cells are more sensitive 
to melflufen than normal cells
D492 is a breast epithelial progenitor cell line that can gen-
erate luminal and myoepithelial cells in monolayer culture 
while in 3D culture it forms elaborate branching structures 
akin to terminal duct lobular units (TDLUs) in the breast2-4 
(Figure S1, left). D492HER2 is an oncogenic derivative of 
D492 generated by overexpressing the ErbB2(HER2) on-
cogene and in 3D culture it forms grape- and spindle-like 
colonies5 (Figure S1, right). Due to their isogenic nature and 
serum free cell culture condition, D492 and D492HER2 are 
ideal for drug screening.
Here, we compared the efficacy of melphalan and 
melflufen in 2D and 3D culture in D492 and D492HER2 cell 
lines. D492 and D492HER2 cells were treated with different 
doses of melphalan and melflufen. Melphalan was added in 
concentrations ranging from 0.1 µmol L-1 up to 100 µmol L-1 
while, concentrations for melflufen were in the range from 
0.1 µmol L-1 to 2 µmol L-1 (Figure 1A).
D492HER2 cells showed increased sensitivity to mel-
phalan compared to the progenitor cell line D492 (Figure 1A, 
left). However, concentration as high as 100 µmol L-1 was in-
sufficient to kill the whole cell population. In both cell lines, 
around 40% of D492 cells and at least 20% of D492HER2 
cells were still viable after incubation with 100 µmol L-1 
melphalan. On the contrary, melflufen decreased viability 
of both D492 and D492HER2 cells at much lower doses 
(Figure  1A, right). While around 60% of the D492 cells 
were still viable at 1 µmol L-1 dose of melflufen, D492HER2 
cells were reduced to less than 10%. Importantly, viability 
of D492HER2 cells was significantly more affected by treat-
ment with melflufen compared to D492 for all doses inves-
tigated. The IC50 numbers, 48h post drug application, show 
that D492HER2 cells were nearly 10 times more sensitive 
to melflufen than D492 cells (Figure  1B). Collectively, 
this demonstrates that melflufen is more potently affecting 
the cancerous D492HER2 cell line than its normal-derived 
isogenic cell line D492.
It is well-known that gene expression in cells is highly de-
pendent on the external environment such as composition of 
cell culture media and the surrounding microenvironment.6 
Thus, whether cells are cultured in monolayer (2D) or in 3D 
extracellular matrix can greatly affect their gene expression. It 
is, therefore, likely that cells respond differently to drugs when 
cultured in 2D vs 3D environment. To address this, we seeded 
D492 and D492HER2 cells on top of reconstituted basement 
membrane (rBM, Matrigel). In this assay, cells can gener-
ate colonies that capture their phenotypic traits better than 
in 2D culture. In 3D environment, D492 cells form TDLU 
like structures whereas D49HER2 cells form grape-like and/
or mesenchymal like colonies (Figure 1C, i and Figure S1). 
When 3D cultures of D492 and D492HER2 cells were treated 
with various doses of melphalan and melflufen, the cultures 
lost their morphogenetic features in a dose dependent man-
ner (Figure 1C, i). Interestingly, while in 2D culture, both cell 
lines showed severe signs of apoptosis already with 1 μmol L-1 
melflufen (Figure 1C, ii), concentrations needed to be raised 
to 10  μmol L-1 and 20  μmol L-1 for D492HER2 and D492 
cells, respectively, in order to see any effect on colony growth 
and morphogenesis in 3D culture (Figure 1C, i)). Again, car-
cinogenic D492HER2 cells were more sensitive to melflufen 
exposure than D492 cells. Similar concentrations of mel-
phalan did not affect the cells in same manner (Figure 1C, i).
3.2 | Melflufen activity is modulated by 
aminopetidases
As the lipophilic drug melflufen readily penetrates cell 
membranes, its cytotoxic effect is largely based on accu-
mulation of its more hydrophilic metabolites within cells. 
Aminopeptidases are thought to be responsible for the cleav-
age of melflufen, and indeed, in our model, the aminopepti-
dase inhibitor bestatin attenuated the activity of melflufen in 
D492HER2 cells (Figure 2A, right). Interestingly, in D492 
cells, preincubation with bestatin showed no effect on mel-
flufen activity (Figure 2A, left).
CD13 is the most studied member of the aminopeptidase 
family and evaluation of endogenous CD13 expression levels 
revealed that D492HER2 cells have a 1.6-fold increased ex-
pression level (Figure  S2) when compared to D492 cells. In 
order to elucidate the importance of CD13 on sensitivity of 
D492 and D492HER2 cells to melflufen, we sorted D492 and 
D492HER2 cells into CD13high and CD13low expressing cell 
populations and subsequently treated these cells with melflufen. 
Interestingly, while no significant difference could be seen in 
neither CD13high or CD13low populations in D492 cells, the 
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D492HER2 CD13high cell population was more sensitive to 
melflufen than D492HER2 CD13low cells (Figure  2B). This 
strongly indicates that high expression of CD13 is important 
for increased efficacy of melflufen in this tumorigenic cell line.
Although CD13 has been in the spotlight as the amino-
peptidase responsible for the action of melflufen, the fam-
ily of aminopeptidases is large, and it is possible that other 
aminopeptidases play a role as well. Here, we used siRNA 
to knock down three aminopeptidases, CD13, LAP3, and 
DPP7 in D492 and D492HER2 cells, and evaluated whether 
this affected the sensitivity of the cells toward melflufen. 
Successful knockdown of target aminopeptidases was con-
firmed by western blot (Figure S3). Indeed, with knockdown 
of either CD13 or LAP3, D492HER2 cells become less sensi-
tive toward melflufen. On the contrary, knockdown of DPP7 
had little effect except when cells were treated with high 
doses (2 µmol L-1) of melflufen (Figure 2C). Collectively, 
this demonstrates that the activity of melflufen is highly de-
pendent on the presence and activity of aminopeptidases and 
that CD13, as well as other aminopeptidases are involved.
3.3 | Melflufen is more potent than 
doxorubicin in treatment of D492HER2 and 
MDA-MB-231 in vitro
Doxorubicin is a commonly used chemotherapeutic agent in 
the treatment of breast cancer. Therefore, we were intrigued 
to compare the efficacy of melflufen and doxorubicin on cell 
viability in our breast cell lines. Indeed, we showed that both 
D492 and D492HER2 cells are more sensitive to melflufen 
than doxorubicin treatment. While doses of up to 2  µmol 
L-1 melflufen decreased cell viability dramatically in both 
cell lines, a dose in the range of 5 µmol L-1 to 10 µmol L-1 
of doxorubicin caused a decrease in viability of these cells 
(Figure 3A). IC50 values for melflufen of 0.046 µmol L-1 in 
D492HER2 cells and 0.52 µmol L-1 in D492 cells compared to 
doxorubicin values of 0.92 µmol L-1 for D492HER2 cells and 
1.8 µmol L-1 for D492 underpin these findings (Figure 3B). 
Having established this, we were also keen to test the effect of 
melflufen on the commonly used triple-negative breast can-
cer cell line MDA-MB231. While these cells tolerated higher 
drug concentrations for both drugs compared to our D492 cell 
lines, melflufen was significantly more efficient than doxoru-
bicin in killing the MDA-MB-231 cells (Figure 3C).
3.4 | Melflufen induces DNA damage in 
sensitive cells
In order to elucidate in more detail, the mechanism of action of 
melflufen we analysed the amount of DNA damage in all three 
different cell lines after treatment with melflufen. In particular, 
we looked at the phosphorylation status of the protein H2AX 
and accumulation patterns of 53BP1, two proteins which have 
previously been shown to be involved in DNA damage.7 We 
observed a dose-dependent increase in the phosphorylation 
of H2AX (ƴH2AX) in all three cell lines upon treatment with 
melflufen(Figure 4A and B, additional western blots used for sta-
tistical evaluation are shown in Figure S5A). Furthermore, time 
course experiments using a 1 µmol L-1 single dose of melflufen 
revealed that melflufen was able to induce stable DNA damage 
for at least 24 h after treatment (Figure 4C) which increased over 
time (Figure 4D,, additional western blots used for statistical eval-
uation are shown in Figure S5B). To analyse these findings in 
more detail we performed immunofluorescence staining of cells 
treated with melflufen. When treated with melflufen in 2D cul-
ture, both carcinogenic cell lines, D492HER2 and MDA-MB231 
showed increased levels of ƴH2AX (Figure 4E), whereas D492 
cells were minimally affected. Similar doses of melphalan only 
resulted in minor increase in ƴH2AX compared to melflufen. In 
addition, in 3D culture, a 10 µmol L-1 dose of melflufen resulted 
in increased ƴH2AX staining (Figure 4F) as well as increased 
levels of 53BP1 (Figure S4) in contrast to melphalan that did not 
lead to such drastic increases at comparable doses. Again, both 
tumorigenic cell lines showed higher levels of DNA damage than 
the D492 cell line. Furthermore, increasing amounts of melflufen 
lead to cellular apoptosis in a dose dependent manner as revealed 
by Western blot for cleaved caspase-3 (Figure 4G and H, addi-
tional western blots used for statistical evaluation are shown in 
Figure S5C) and cleaved PARP(Figure S5D) 24 h post-treatment.
3.5 | Melflufen is superior to doxorubicin 
in reducing the metastatic potential of MDA-
MB-231 cells in vivo
To evaluate the anti-neoplastic activity of melflufen in vivo, we 
xenografted D492HER2 and MDA-MB-231 cells on chicken 
chorioallantoic membranes (CAM) and treated formed tumors 
with 50  µmol L-1 melflufen or doxorubicin. Analysis of the 
tumors recovered after the treatment showed that both drugs 
F I G U R E  1  Melphalan and melflufen reduce cell viability of cancerous breast epithelial cells more efficiently than isogenic normal epithelial 
cells. (A) D492 and D492HER2 cells were seeded in 96 well plates and treated with various concentrations of either melphalan or melflufen 
and cell viability was assessed 48 h post-treatment. Shown are means ± standard deviation ( n = 3). (B) From the mean of three independent 
experiments, IC50 values were calculated. Concentrations are presented in log scale on x axes while y axes represent cell viability. n = 3. (C) D492 
and D492HER2 cells were cultured on top of reconstituted basement membrane (rBM) to generate branching and grape/spindle-like structures 
respectively. After colony formation, cells were incubated with indicated concentrations of either melphalan or melflufen and phenotypic changes 
monitored. Scalebar = 100 μm
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F I G U R E  2  Melflufen activity is modulated by aminopeptidases. (A) D492 and D492HER2 cells were pretreated with the aminopeptidase 
inhibitor bestatin (10 µmol L-1) for 1 h prior to incubation with increasing concentrations of melflufen and cell viability analysed 48 h later. Shown 
are means ± standard deviation (n = 3). (B) CD13 high and low FACS sorted D492 and D492HER2 cell populations were incubated with indicated 
amounts of melflufen for 2 h. Cell proliferation was analysed via an Incucyte and cell viability calculated after 48 h. Shown are means ± standard 
deviation (n = 3). (C) D492HER2 cells were siRNA depleted for specific aminopeptidases as indicated. 24 h post depletion, cells were incubated 
with indicated concentrations of melflufen and cell viability analysed via Incucyte. Shown are means ± standard deviation (n = 3)
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were equally effective in inhibiting tumor growth compared 
to untreated control (Figure  5A). Interestingly, detection of 
MDA-MB-231 cells at the lower CAM by qPCR allowed for 
quantification of disseminated metastatic cells and revealed that 
melflufen is superior to doxorubicin in reducing the metastatic 
spread. While doxorubicin treatment resulted in around 60% 
metastatic regression, melflufen treatment led to a 90% regres-
sion rate (Figure 5B). As D492HER2 cells did not show any me-
tastasis potential in this assay the effect could not be measured.
4 |  DISCUSSION
In this study, we have demonstrated that melflufen is an ef-
ficient drug in the treatment of breast cancer cells in vitro 
and in vivo. Furthermore, we showed that tumorigenic 
breast cancer cell lines MDA-MB231 and D492HER2 are 
more sensitive to melflufen than the non-tumorigenic D492 
cell line. Importantly, we also showed that context mat-
ters, as cells cultured in 3D conditions were less sensitive 
to melflufen than cells in 2D monolayer culture. This is in 
agreement with previous studies that have shown that cel-
lular behavior and drug sensitivity is different between 2D 
and 3D conditions.8-11 Cells cultured in 2D have lost their 
polarity and their differentiation profile is different from the 
one seen in vivo resulting in altered cell signaling and gene 
expression, which eventually may affect drug sensitivity.12,13 
In contrast, cells cultured in 3D microenvironment in vitro 
can capture phenotypes as evidenced by the generation of 
structures akin to the condition in tissues and organs in the 
F I G U R E  3  Melflufen reduces cell 
viability to a larger extent than doxorubicin. 
(A) D492 and D492HER2 cells were 
incubated with indicated concentrations of 
either melflufen or doxorubicin for 30 min. 
48 h post-treatment, cell viability was 
analysed via Prestoblue staining. Shown 
are means ± standard deviation (n = 3). 
(B) From the mean of three independent 
experiments, IC50 values were calculated. 
Concentrations are presented in log scale on 
x axes while y axes represent cell viability. 
(C) Triple-negative cell line MDA-MB231 
was incubated with indicated concentrations 
of melflufen or doxorubicin for 30 min 
and cell viability analysed via Prestoblue 
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human body.13 Although 3D cultures are not perfect models, 
they represent a link between conventional cell cultures and 
in vivo conditions. Lovitt and co-workers demonstrated re-
cently that breast cancer cells acquired increased resistance 
against doxorubicin when cells were cultured in 3D, and this 
was due to altered β1-integrin signaling.8 By blocking β1-
integrin signaling in MDA-MB231 cells in 3D culture, they 
showed that the cells acquired an increased sensitivity toward 
doxorubicin treatment, which further supports accumulating 
evidence that the microenvironment is important for drug ef-
ficacy.8 For this reason, it is plausible that activation of sur-
vival pathways achieved in the 3D environent is contributing 
to decreased melflufen sensitivity as well.
Aminopeptidases, in particular CD13 also known as 
ANPEP, have been shown to be important activators of 
melflufen by cleavage of melflufen into the hydrophilic mel-
phalan and para-fluoro-L-phenylalanine.14,15 In addition to 
its enzymatic activity, CD13 is also known for other functions 
such as receptor and signaling mechanisms.16 Due to high ex-
pression of aminopeptidases in many cancer types, aminopep-
tidase inhibitors are considered attractive tools for combination 
regimens in anti-cancer treatment..16,17 For breast cancer, it has 
been shown that aminopeptidase activity is increased in neo-
plastic tissue 18 and in a previous study 36.2% of studied breast 
cancer patients were positive to CD13 which significantly cor-
related with tumor type, neoangiogenesis and life expectancy.19
F I G U R E  5  In vivo effects of 
Melflufen on MDA-MB-231 cells. (A) 
D492HER2 and MDA-MB231 cells were 
xenograted on chicken chorioallantoic 
membranes (CAM) and formed tumors 
were treated with 50 µmol L-1 melfufen or 
doxorubicin and analyzed by weight. Shown 
are means ± standard deviation (n = 15). 
(B) To analyze for anti-metastatic potential, 
genomic DNA was extracted from the CAM 
and analyzed by qPCR with specific primers 























































F I G U R E  4  Meflufen induces DNA damage and apoptosis in cancer cells. (A) D492, D492HER2, and MDA-MB231 cells were seeded 
on a six well plate and incubated with either none, 1 µmol L-1 or 5 µmol L-1 melflufen for 30 min and harvested 3 h post-treatment. Equally 
loaded protein lysates subjected for immunoblotting for H2AX/ yH2Ax One representative blot of three is shown. (B) Quantification of protein 
bands of three independent experiments performed in 4A. Actin was used as loading control. Quantification was perfomed by FIJI. Shown are 
means ± standard deviation (n = 3). (C) D492, D492HER2, and MDA-MB231 cells were incubated with 1 µmol L-1 of melflufen for 30 min and 
harvested on indicated timepoints and subjected for immunoblotting for H2AX/ yH2Ax. One representative blot of 3 is shown. (D) Quantification 
of protein bands of three independent experiments performed in 4C. Actin was used as loading control. Quantification was perfomed by FIJI. 
Shown are means ± standard deviation (n = 3). (E) D492, D492HER2, and MDA-MB231 cells were cultured in monolayer and 24 h after 
treatment with none, 1 µmol L-1 or 5 µmol L-1 melflufen or melphalan, cells were fixed and stained for yH2Ax (red). IF analysis reveals that 
melflufen increases DNA damage in a dose dependent manner. Melphalan shows only a minor increase in staining at the concentrations used. 
Scalebar = 30 μm. (F) For immunostaining of D3 cultures, colonies of D492, D492HER2 and MDA-MB231 were incubated with either 10 µmol 
L-1 melflfufen or melphalan for 2h, fixed 72h post-treatment and stained for yH2Ax (red) and DAPI (blue). Scalebar = 100 µm (G) D492HER2 and 
MDA-MB231 cells were incubated with increasing amounts of melflufen for 24 h, harvested in RIPA buffer and subjected to immunoblotting for 
cleaved caspase-3. One representative blot of 3 is shown. (H) Quantification of protein bands of 3 independent experiments performed in 4G for 
caspase-3. Actin was used as loading control. Quantification was perfomed by FIJI. Shown are means ± standard deviation (n = 3)
6736 |   SCHEPSKY Et al
We demonstrated that melflufen activity was greatly re-
duced in cancer cells if cells were pretreated with the ami-
nopeptidase inhibitor, bestatin. Furthermore, by enriching 
D492HER2 cells into CD13high and CD13low cell populations 
we showed that melflufen was significantly more active in 
the CD13high population. Interestingly, we did not observe 
significant differences between CD13high and CD13low cell 
population in the nontumorigenic cell line D492. Analysis of 
endogenous CD13 expression levels revealed that D492HER2 
cells have approximately an 1.6-fold increase in CD13 expres-
sion compared to D492 cells (Figure S2). It is possible that 
the nontumorigenic D492 cell line is less dependent on CD13 
expression and activity, while the presence of CD13 plays a 
more important role in the tumorigenic D492HER2 line. It 
could also be that CD13 and other aminopeptidases are used 
as a defense mechanism by tumorigenic cells whereas normal 
cells are less dependent on this function. For example, Dixon 
and co-authors detected CD13 expression in breast epithe-
lium and in 20% of breast cancer samples analyzed which 
affected doxorubicin resistance.20 Hence, slightly higher ex-
pression levels of CD13 could lead to higher enzyme activ-
ity in these cells and influence melflufen activity to a higher 
extent. Therefore, if CD13 activity is elevated and mediating 
resistance against doxorubicin melflufen application might 
be a good alternative treatment.
In that respect, it is of interest to note that to date, 
melflufen has been tested mostly in late stage or relapsed 
myeloma where cancer cells have survived several anti-can-
cer treatments and therefore have probably intensified their 
survival mechanisms. As aminopeptidases are part of these 
survival mechanisms, this could explain why cancer cells 
are more sensitive to melflufen treatment than normal cells. 
Further studies as well as gene expression and protein activ-
ity analysis are needed to shed more light on this.
We also demonstrated that knock down of CD13 in 
D492HER2 cells reduced the efficacy of melflufen fur-
ther demonstrating the importance of CD13 for the activity 
of melflufen in D492HER2 cells. The efficient activity of 
melflufen in cancer cells has been documented in several 
articles (reviewed in 21). Chauhan et al demonstrated that 
melflufen was highly efficient in killing myeloma cells, 
even cells that had acquired resistance to melphalan.22 
Most studies on the efficacy of melflufen so far have been 
on haematological cancer, however, accumulating evidence 
points toward efficacy in solid cancer as well.23 In their 
paper, Delforoush and co-workers demonstrated the efficacy 
of melflufen in lymphoma cells in vitro and in a xenograft 
model in vivo.23 Furthermore, Charlier et al demonstrated 
potency of melflufen on ovarian cancer cells in vitro and in 
vivo.24 Although CD13 has been in the spotlight as the main 
activator of melflufen, other aminopeptidases may also play 
a role. Fang and colleagues just recently showed that LAP3 
is involved in migration and invasion of breast cancer cells.25 
Accordingly, we demonstrated that knock down of LAP3 and 
DPP7 in D492HER2 cells reduced the positive activity of 
melflufen indicating that other aminopeptidases could play 
a role in breast cancer treatment, an important finding which 
needs further evaluation.When compared to the commonly 
used breast cancer drug doxorubicin we were able to show 
that melflufen is more potent both in vitro and in vivo. D492, 
D492HER2, and MDA-MB231 cell lines were more sensi-
tive to melflufen than doxorubicin, both in monolayer and in 
3D culture. Furthermore, in an in vivo CAM assay, melflufen 
was similarly effective in decreasing tumor size stemming 
from D492HER2 and MDA-MB231 cells, but was more ef-
fective in reducing the metastatic potential of MDA-MB231 
cells. The slightly higher efficacy of doxorubicin on tumor 
growth in the CAM assay is statistically not significant but 
could be explained by differences in bioavailability of the 
drugs due to rapid melflufen absorption.
Melflufen-derived melphalan metabolites are known in-
ducers of DNA damage by DNA double strand breaks.26 The 
phosphorylation of histone H2AX (ƴH2AX) at sites near 
DNA breaks is an early event in the response of mamma-
lian cells to damage.27 In our assays, we could show robust 
phosphorylation of H2AX after melflufen application in a 
dose dependent manner. While statistical analysis of three 
independent experiments in both assays showed no or only 
minor significance between treated samples the results still 
represent a trend that phosphorylation of H2Ax is caused by 
treatment of cells with melflufen. In addition, Western blot 
analysis demonstrated that melflufen-induced DNA dam-
age resulted in apoptosis through activation of caspases-3 
and PARP cleavage. Previous studies have shown that 
melflufen induced DNA damage and apoptosis is not depen-
dent on p53.22 This is of particular interest as the D492 and 
D492HER2 cells are p53 deficient 2 and therefore cannot un-
dergo apoptosis through the regular p53 pathway. Our find-
ings could have important clinical implications as it has been 
shown that p53 mutations occur in more aggressive forms of 
breast cancer 28 and are associated with worse prognosis.29 
Therapeutic treatment with melflufen could present a valid 
therapeutic approach for these patient populations.
In recent years, organoid cultures have entered the spot-
light as a powerful method for drug screening. It has been 
shown that culturing breast organoids in 3D retains the mo-
lecular signature of the original tumor.30 Having patient-de-
rived breast organoids profiled for expression of distinct type 
of aminopeptidases as well as p53 could identify those pa-
tients that could possibly benefit from melflufen treatment.
The fact that the highly lipophilic melflufen is converted 
to hydrophilic metabolites inside cells with high expression 
of aminopeptidases defines melflufen as a potential drug 
for targeted therapy and personalized medicine. However, 
due to its rapid intracellular uptake21 melflufens distribu-
tion and its ability to penetrate the core of solid tumors 
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requires further investigation. Furthermore, it is not known 
how the microenviroment of the tumor influences the ac-
tivity of melflufen as has been shown with doxorubicin.8 
Therefore, it would be of the utmost interest to analyse the 
effects of melflufen in more detail in 3D culture and cell 
co-culture.
5 |  CONCLUSION
In summary, we have demonstrated that the lipophilic 
peptide-conjugated alkylator melflufen shows high effi-
cacy in carcinogenic breast cell lines compared to their 
normal counterparts in vitro. This efficacy depends on 
aminopeptidases such as CD13, LAP3, and DPP7, which 
are shown to be associated with an aggressive phenotype. 
For this reason, melflufen might provide a new treatment 
option for breast cancer patients and deserves further 
investigation.
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